GlassScriptPhysician profile
Sumit Shah
NPI 1346439213
$41,215.67
in general payments reported to CMS, 2019-2025
10 companies · $8,033 in 2025
The $8,033 reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.22 · 2022: $265 · 2023: $7,348 · 2024: $26K · 2025: $8,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $6,426 · Travel and Lodging: $3,425 · Honoraria: $1,390 · Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,652.51 |
| Consulting Fee | $6,426.00 |
| Travel and Lodging | $3,425.24 |
| Honoraria | $1,390.00 |
| Food and Beverage | $1,031.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31,652.66 | 2021-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $7,357.56 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $1,456.16 | 2022-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $245.67 | 2023-2024 | Izervay |
| Genentech, INC. | $207.20 | 2022 | |
| Abbvie INC. | $181.14 | 2023-2025 | Ozurdex |
| Genentech USA, INC. | $64.99 | 2022-2023 | Vabysmo, Lucentis |
| Coherus Oncology, INC. | $32.33 | 2023 | |
| Ani Pharmaceuticals, INC. | $17.96 | 2025 | Yutiq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.